{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:46:36Z","timestamp":1790999196736,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms. KarXT, a novel combination of xanomeline and trospium, offers potential therapeutic benefits for schizophrenia treatment by targeting muscarinic receptors and avoiding dopamine receptor blockade. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of KarXT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PubMed, Scopus, Web of Science, and Cochrane databases were systematically searched for relevant randomized controlled trials (RCTs) up to October 2024. Studies involving adult patients with schizophrenia treated with KarXT were included. Furthermore, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was used to assess evidence quality, and the risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Four studies with 690 participants were included. KarXT significantly reduced Positive and Negative Syndrome Scale (PANSS) total scores compared to placebo (mean difference (MD): -13.77, 95% confidence interval (CI) [-22.33 to -5.20], P-value\u2009=\u20090.002), with significant improvements in positive and negative subscale scores. It significantly increased the incidence of achieving\u2009\u2265\u200930% PANSS score reduction (risk ratio: 2.15, 95% CI [1.64 to 2.84], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001). Moreover, KarXT demonstrated a favorable safety profile, with side effects such as nausea and constipation being mild and transient. Notably, it was not significantly associated with weight gain or extrapyramidal symptoms, which are common with traditional antipsychotics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>KarXT\u2019s distinct mechanism and tolerability highlight its potential to address unmet needs in schizophrenia treatment. Future studies should explore its long-term efficacy, delayed adverse effects, and comparative effectiveness against existing therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12888-025-06696-5","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T14:12:36Z","timestamp":1743516756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Hazem E.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menna A.","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef Magdy","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ayman","family":"Shawky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"6696_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195\u2013203.","journal-title":"Schizophr Bull"},{"key":"6696_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1542\/pir.34.7.296","volume":"34","author":"S Abidi","year":"2013","unstructured":"Abidi S. Psychosis in children and youth: focus on early-onset schizophrenia. Pediatr Rev. 2013;34:296\u2013305. quiz 305.","journal-title":"Pediatr Rev"},{"key":"6696_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376.","journal-title":"Epidemiol Rev"},{"issue":"8 Suppl","key":"6696_CR4","first-page":"S160","volume":"20","author":"DC Javitt","year":"2014","unstructured":"Javitt DC. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview. Am J Manag Care. 2014;20(8 Suppl):S160\u20135.","journal-title":"Am J Manag Care"},{"key":"6696_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S, Schizophrenia. Lancet. 2009;374:635\u201345.","journal-title":"Lancet"},{"key":"6696_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnstone M, McKenna PJ, Schizophrenia. Lancet. 2022;399:473\u201386.","journal-title":"Lancet"},{"key":"6696_CR7","doi-asserted-by":"crossref","unstructured":"Sher L, Kahn RS. Suicide in schizophrenia: an educational overview. Med (Kaunas). 2019;55.","DOI":"10.3390\/medicina55070361"},{"key":"6696_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000074279","volume":"17","author":"DL Sultzer","year":"2004","unstructured":"Sultzer DL. Psychosis and antipsychotic medications in Alzheimer\u2019s disease: clinical management and research perspectives. Dement Geriatr Cogn Disord. 2004;17:78\u201390.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"6696_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway. Schizophr Bull. 2009;35:549\u201362.","journal-title":"Schizophr Bull"},{"key":"6696_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/14737175.2022.2092402","volume":"22","author":"GM Giordano","year":"2022","unstructured":"Giordano GM, Caporusso E, Pezzella P, Galderisi S. Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. Expert Rev Neurother. 2022;22:541\u201355.","journal-title":"Expert Rev Neurother"},{"key":"6696_CR11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","volume":"50","author":"RR Conley","year":"2001","unstructured":"Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50:898\u2013911.","journal-title":"Biol Psychiatry"},{"key":"6696_CR12","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","volume":"381","author":"SR Marder","year":"2019","unstructured":"Marder SR, Cannon TD, Schizophrenia. N Engl J Med. 2019;381:1753\u201361.","journal-title":"N Engl J Med"},{"key":"6696_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/mds.26527","volume":"31","author":"C Marras","year":"2016","unstructured":"Marras C, Lang A, van de Warrenburg BP, Sue CM, Tabrizi SJ, Bertram L, et al. Nomenclature of genetic movement disorders: recommendations of the international Parkinson and movement disorder society task force. Mov Disord. 2016;31:436\u201357.","journal-title":"Mov Disord"},{"key":"6696_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0924-977X(96)00041-7","volume":"7","author":"CH Miller","year":"1997","unstructured":"Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol. 1997;7:51\u20135.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6696_CR15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.4088\/JCP.tv17016ah4c","volume":"78","author":"CU Correll","year":"2017","unstructured":"Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78:1136\u201347.","journal-title":"J Clin Psychiatry"},{"key":"6696_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4088\/JCP.v60n0602","volume":"60","author":"DA Wirshing","year":"1999","unstructured":"Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358\u201363.","journal-title":"J Clin Psychiatry"},{"key":"6696_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1941875210386491","volume":"1","author":"BD Berman","year":"2011","unstructured":"Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1:41\u20137.","journal-title":"Neurohospitalist"},{"key":"6696_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/NDT.S455279","volume":"20","author":"A Peng","year":"2024","unstructured":"Peng A, Chai J, Wu H, Bai B, Yang H, He W, et al. New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists. Neuropsychiatr Dis Treat. 2024;20:607\u201320.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6696_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s13311-015-0382-6","volume":"12","author":"MW Manseau","year":"2015","unstructured":"Manseau MW, Goff DC. Cannabinoids and schizophrenia: risks and therapeutic potential. Neurotherapeutics. 2015;12:816\u201324.","journal-title":"Neurotherapeutics"},{"key":"6696_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fncel.2013.00055","volume":"7","author":"E Scarr","year":"2013","unstructured":"Scarr E, Gibbons AS, Neo J, Udawela M, Dean B. Cholinergic connectivity: it\u2019s implications for psychiatric disorders. Front Cell Neurosci. 2013;7:55.","journal-title":"Front Cell Neurosci"},{"key":"6696_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41537-020-0105-9","volume":"6","author":"M Caton","year":"2020","unstructured":"Caton M, Ochoa ELM, Barrantes FJ. The role of nicotinic cholinergic neurotransmission in delusional thinking. NPJ Schizophr. 2020;6:16.","journal-title":"NPJ Schizophr"},{"key":"6696_CR22","doi-asserted-by":"publisher","first-page":"108003","DOI":"10.1016\/j.heares.2020.108003","volume":"402","author":"BD Richardson","year":"2021","unstructured":"Richardson BD, Sottile SY, Caspary DM. Mechanisms of GABAergic and cholinergic neurotransmission in auditory thalamus: impact of aging. Hear Res. 2021;402:108003.","journal-title":"Hear Res"},{"key":"6696_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1749-6632.1999.tb11332.x","volume":"868","author":"KA Radcliffe","year":"1999","unstructured":"Radcliffe KA, Fisher JL, Gray R, Dani JA. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann N Y Acad Sci. 1999;868:591\u2013610.","journal-title":"Ann N Y Acad Sci"},{"key":"6696_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","volume":"269","author":"HE Shannon","year":"1994","unstructured":"Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther. 1994;269:271\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"6696_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","volume":"9","author":"NR Mirza","year":"2003","unstructured":"Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9:159\u201386.","journal-title":"CNS Drug Rev"},{"key":"6696_CR26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","volume":"240","author":"A Breier","year":"2023","unstructured":"Breier A, Brannan SK, Paul SM, Miller AC. Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology. 2023;240:1191\u20138.","journal-title":"Psychopharmacology"},{"key":"6696_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717\u201326.","journal-title":"N Engl J Med"},{"key":"6696_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403:160\u201370.","journal-title":"Lancet"},{"key":"6696_CR29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","volume":"81","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, et al. Efficacy and safety of Xanomeline-Trospium chloride in schizophrenia: A randomized clinical trial. JAMA Psychiatry. 2024;81:749\u201356.","journal-title":"JAMA Psychiatry"},{"key":"6696_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/d41573-024-00155-8","volume":"23","author":"K Kingwell","year":"2024","unstructured":"Kingwell K. FDA approves first schizophrenia drug with new mechanism of action since 1950s. Nat Rev Drug Discov. 2024;23:803\u2013803.","journal-title":"Nat Rev Drug Discov"},{"key":"6696_CR31","first-page":"624","volume":"30","author":"A McKenna","year":"2024","unstructured":"McKenna A, Tice JA, Whittington MD, Wright AC, Richardson M, Raymond FR, et al. KarXT for schizophrenia-effectiveness and value: A summary from the Institute for clinical and economic review\u2019s new England comparative effectiveness public advisory Council. J Manag Care Spec Pharm. 2024;30:624\u20138.","journal-title":"J Manag Care Spec Pharm"},{"key":"6696_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","volume":"274","author":"AC Wright","year":"2024","unstructured":"Wright AC, McKenna A, Tice JA, Rind DM, Agboola F. A network meta-analysis of KarXT and commonly used Pharmacological interventions for schizophrenia. Schizophr Res. 2024;274:212\u20139.","journal-title":"Schizophr Res"},{"key":"6696_CR33","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65\u201394.","journal-title":"Ann Intern Med"},{"key":"6696_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"6696_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4088\/JCP.v58n1205","volume":"58","author":"SR Marder","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G. The effects of Risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538\u201346.","journal-title":"J Clin Psychiatry"},{"key":"6696_CR36","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"6696_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"6696_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0269881103174013","volume":"17","author":"TRE Barnes","year":"2003","unstructured":"Barnes TRE. The Barnes akathisia rating Scale\u2013revisited. J Psychopharmacol (Oxford). 2003;17:365\u201370.","journal-title":"J Psychopharmacol (Oxford)"},{"key":"6696_CR39","doi-asserted-by":"crossref","unstructured":"Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M, Tardive Dyskinesia Assessment Working Group. Revisiting the abnormal involuntary movement scale: proceedings from the tardive dyskinesia assessment workshop. J Clin Psychiatry. 2018;79.","DOI":"10.4088\/JCP.17cs11959"},{"key":"6696_CR40","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"6696_CR41","unstructured":"The Cochrane Collaboration. Review manager web (RevMan web). Version 5.4. Computer software. The Cochrane Collaboration; 2021."},{"key":"6696_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"6696_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129\u201341.","journal-title":"J Clin Epidemiol"},{"key":"6696_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142\u201352.","journal-title":"J Clin Epidemiol"},{"key":"6696_CR45","doi-asserted-by":"crossref","unstructured":"Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM. Antipsychotic efficacy of KarXT (Xanomeline-Trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry. 2022;83.","DOI":"10.4088\/JCP.21m14316"},{"key":"6696_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","volume":"179","author":"SM Paul","year":"2022","unstructured":"Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179:611\u201327.","journal-title":"Am J Psychiatry"},{"key":"6696_CR47","volume-title":"StatPearls. Treasure Island","author":"RS D\u2019Souza","year":"2024","unstructured":"D\u2019Souza RS, Hooten WM. Extrapyramidal symptoms. StatPearls. Treasure Island. (FL): StatPearls Publishing; 2024."},{"key":"6696_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","volume":"161","author":"S Janno","year":"2004","unstructured":"Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004;161:160\u20133.","journal-title":"Am J Psychiatry"},{"key":"6696_CR49","doi-asserted-by":"publisher","first-page":"656370","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.","journal-title":"Biomed Res Int"},{"key":"6696_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euroneuro.2024.11.013","volume":"92","author":"N Fabiano","year":"2025","unstructured":"Fabiano N, Wong S, Zhou C, Correll CU, H\u00f8jlund M, Solmi M. Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2025;92:62\u201373.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6696_CR51","doi-asserted-by":"crossref","unstructured":"Menegaz de Almeida A, Moraes Tamashiro F, Cavalcanti Souza ME, Luiz Silv\u00e9rio II, de Almeida Souza Miranda C, Barros Andrade \u00cd et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis. J Psychiatr Res. 2025;181:262\u201372.","DOI":"10.1016\/j.jpsychires.2024.11.047"},{"key":"6696_CR52","unstructured":"10.4. 3.1 Recommendations on testing for funnel plot asymmetry. https:\/\/handbook-5-1.cochrane.org\/chapter_10\/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm. Accessed 10 May 2023."},{"key":"6696_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","volume":"274","author":"WP Horan","year":"2024","unstructured":"Horan WP, Targum SD, Claxton A, Kaul I, Yohn SE, Marder SR, et al. Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials. Schizophr Res. 2024;274:57\u201365.","journal-title":"Schizophr Res"},{"key":"6696_CR54","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dub\u00e9 S, Mallinckrodt C, et al. Selective muscarinic receptor agonist Xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033\u20139.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"6696_CR55","first-page":"38","volume":"19","author":"M Carbon","year":"2014","unstructured":"Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19(Suppl 1):38\u201352. quiz 35.","journal-title":"CNS Spectr"},{"key":"6696_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"CU Correll","year":"2020","unstructured":"Correll CU, Schooler NR. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519\u201334.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6696_CR57","doi-asserted-by":"publisher","first-page":"104257","DOI":"10.1016\/j.nbd.2018.08.016","volume":"131","author":"FC Nucifora","year":"2019","unstructured":"Nucifora FC, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.","journal-title":"Neurobiol Dis"},{"key":"6696_CR58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","volume":"5","author":"S Galderisi","year":"2018","unstructured":"Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5:664\u201377.","journal-title":"Lancet Psychiatry"},{"key":"6696_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","volume":"24","author":"G Foussias","year":"2014","unstructured":"Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014;24:693\u2013709.","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06696-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06696-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06696-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T14:12:53Z","timestamp":1743516773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06696-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6696"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06696-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Our manuscript was not applied to human beings and thus requires no ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}